Background/Aim: Although osteoblasts are thought to be the major component of the hematopoietic stem cell niche in the bone marrow microenvironment, the role of osteoblasts in hematopoiesis is still unclear. The ability of human osteoblasts to support early hematopoiesis was investigated. Methods and Results: Human CD34+ bone marrow cells cultured on human osteoblasts were capable of surviving without addition of cytokines and differentiated into myeloid cells with slight proliferation. The results of immunohistochemical experiments suggested activation of FAK and AKT in hematopoietic cells attached to osteoblasts. When stem cell factor, Flt3-L, and IL-3 were added to the coculture system, each cytokine distinctively enhanced proliferation and differentiation of CD34+ bone marrow cells. Conclusion: The results suggest that human osteoblasts have the ability to support hematopoietic cell development in vitro.

Keywords:
Cell adhesion molecule, Cell signaling, Cytokines, Hematopoiesis, Osteoblasts, Stem cell factor
1.
Taichman RS, Emerson SG: The role of osteoblasts in the hematopoietic microenvironment. Stem Cells 1998;16:7–15.
2.
Taichman RS: Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem-cell niche. Blood 2005;105:2631–2649.
3.
Zhang J, Niu C, Ye L, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L: Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003;425:836–841.
4.
Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT: Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003;425:841–846.
5.
Arai F, Hirao A, Ohmura M, Sato H, Matsuoka S, Takubo K, Ito K, Koh GY, Suda T: Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004;118:149–161.
6.
Saito M, Kiyokawa N, Taguchi T, Suzuki K, Sekino T, Mimori K, Suzuki T, Nakajima H, Katagiri YU, Fujimura J, Fujita H, Ishimoto K, Yamashiro Y, Fujimoto J: Granulocyte colony-stimulating factor directly affects human monocytes and modulates cytokine secretion. Exp Hematol 2002;30:1115–1123.
7.
Kiyokawa N, Kokai Y, Ishimoto K, Fujita H, Fujimoto J, Hata J: Characterization of the common acute lymphoblastic leukemia antigen (CD10) as an activation molecule on mature human B cells. Clin Exp Immunol 1990;79:322–327.
8.
Teixido J, Hemler ME, Greenberger JS, Anklesaria P: Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma. J Clin Invest 1992;90:358–367.
9.
Papayannopoulou T, Priestley GV, Nakamoto B: Anti-VLA4/VCAM-1-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 1998;91:2231–2239.
10.
Taichman RS, Emerson SG: Human osteoblasts support hematopoiesis through the production of granulocyte colony-simulating factor. J Exp Med 1994;179:1677–1682.
11.
Taichman RS, Reilly MJ, Emerson SG: Human osteoblasts support human hematopoietic progenitor cells in in vitro bone marrow cultures. Blood 1996;87:518–524.
12.
Ahmed N, Khokher MA, Hassan HT: Cytokine-induced expansion of human CD34+ stem/progenitor and CD34+CD41+ early megakaryocytic marrow cells cultured on normal osteoblasts. Stem Cells 1999;17:92–99.
13.
Wodnar-Filipowicz A: Flt3 ligand: role in control of hematopoietic and immune functions of the bone marrow. News Physiol Sci 2003;18:247–251.
14.
Drouet M, Mathieu J, Grenier N, Multon E, Sotto J-J, Herodin F: The reduction of in vitro radiation-induced Fas-related apoptosis in CD34+ progenitor cells by SCF, FLT-3 ligand, TPO, and IL-3 in combination resulted in CD34+ cell proliferation and differentiation. Stem Cells 1999;17:273–285.
15.
Drouet M, Mourcin F, Grenier N, Leroux V, Denis J, Mayol JF, Thullier P, Lataillade JJ, Herodin F: Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: long-term follow-up of hematopoiesis. Blood 2004;103:878–885.
16.
Lataillade JJ, Clay D, Dupuy C, Rigal S, Jasmin C, Bourin P, Le Bousse-Kerdilès MC: Chemokine SDF-1 enhances circulating CD34+ cell proliferation in synergy with cytokines: possible role in progenitor survival. Blood 2000;95:756–768.
17.
Murdoch C: CXCR4: chemokine receptor extraordinaire. Immunol Rev 2000;177:175–184.
18.
Tokoyoda K, Egawa T, Sugiyama T, Choi B-I, Nagasawa T: Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004;20:707–718.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.